Sanofi
SNY
711 hedge funds and large institutions have $12.6B invested in Sanofi in 2024 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 298 increasing their positions, 203 reducing their positions, and 71 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 298 | Existing positions reduced: 203
23% more call options, than puts
Call options by funds: $76.8M | Put options by funds: $62.4M
18% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 71
1% more funds holding
Funds holding: 707 → 711 (+4)
0.19% more ownership
Funds ownership: 20.17% → 20.36% (+0.19%)
1% less capital invested
Capital invested by funds: $12.7B → $12.6B (-$133M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$312M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$162M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$94.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.1M |
| 5 |
MIS
Morningstar Investment Services
Chicago,
Illinois
|
-$36.4M |
SNY Hedge Fund Activity: Q1 2024 in Review
711 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q1 2024, worth a combined $12.6B — down 1% from $12.7B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new SNY positions and 71 closed out — a net gain of 13 holders — while 298 added to existing stakes and 203 trimmed.
The largest buyer was Barrow, Hanley, Mewhinney & Strauss, opening a new position worth an estimated $136M. The largest seller was Morgan Stanley, cutting an estimated $312M.
- 711 institutional investors held Sanofi (SNY) as of Q1 2024, up from 707 in Q4 2023.
- Funds reported $12.6B of Sanofi stock for Q1 2024, down 1% quarter-over-quarter.
- 84 funds opened new Sanofi positions in Q1 2024 and 71 closed out, a net change of +13 holders.
- The largest Sanofi buyer in Q1 2024 was Barrow, Hanley, Mewhinney & Strauss, an estimated $136M added.
- The largest Sanofi seller in Q1 2024 was Morgan Stanley, an estimated $312M sold.
Based on aggregated 13F filings for Q1 2024.